Evidence map›Paper›PMID 15056408›Full record

ReviewCurrent allergy and asthma reports2004

Implications of a switch from prescription to over-the-counter status for allergy drugs.

Eric P Brass

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Eric P BrassDepartment of Medicine, Harbor-UCLA Center for Clinical Pharmacology, 1124 W. Carson Street, Tornace, CA 90502, USA. ebrass@ucla.edu
UCLA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several drugs for the treatment of allergic conditions, previously available only by prescription, can now be purchased over-the-counter (OTC). The OTC availability of allergy drugs has the potential to increase patient access to these medications. At the same time, OTC availability transfers a number of decisions from the health care provider to the patient and might alter the role of the physician in allergy management. For example, patients must correctly self-diagnosis that their symptoms are due to an allergy, and identify the appropriate type of allergy medication to use. OTC drug availability has economic implications for the patient and physician, as well as for the health care insurance and pharmaceutical industries. Therefore, although OTC access to allergy medications facilitates treatment of allergies by consumers, more research is required to understand the true public health and economic impacts of OTC availability of these drugs.

Indexed as

Anti-Allergic AgentsDrug PrescriptionsNonprescription DrugsDelivery of Health CareHumansRhinitis, Allergic, PerennialSelf CareAnti-Allergic AgentsNonprescription Drugs

Identifiers

PMID15056408
OpenAlexW2050662623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.